Silexion Therapeutics Files 8-K

Ticker: SLXNW · Form: 8-K · Filed: Sep 2, 2025 · CIK: 2022416

Sentiment: neutral

Topics: corporate-update, filing

Related Tickers: SLXN

TL;DR

Silexion Therapeutics (SLXN) filed an 8-K on 9/2/25 with corporate updates and security details.

AI Summary

Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on September 2, 2025, reporting on events as of the same date. The filing indicates the company is incorporated in the Cayman Islands and has its principal executive offices in Ramat-Gan, Israel. It also lists NASDAQ as its exchange and provides details on its ordinary shares and warrants.

Why It Matters

This 8-K filing provides updated corporate information and details about the company's securities, which is important for investors tracking Silexion Therapeutics Corp.

Risk Assessment

Risk Level: low — This filing is a routine corporate update and does not appear to contain significant new risks or material adverse information.

Key Players & Entities

FAQ

What is the former name of Silexion Therapeutics Corp?

The former name of Silexion Therapeutics Corp. was Biomotion Sciences, with a date of name change on May 6, 2024.

When was this 8-K report filed?

This 8-K report was filed on September 2, 2025.

Where are Silexion Therapeutics Corp.'s principal executive offices located?

The principal executive offices of Silexion Therapeutics Corp. are located at 12 Abba Hillel Road, Ramat-Gan, Israel, 5250606.

What is the Commission File Number for Silexion Therapeutics Corp?

The Commission File Number for Silexion Therapeutics Corp. is 001-42253.

On which stock exchange is Silexion Therapeutics Corp. listed?

Silexion Therapeutics Corp. is listed on NASDAQ.

Filing Stats: 562 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2025-09-02 08:31:04

Key Financial Figures

Filing Documents

01

Item 7.01 Regulation FD Disclosure. On September 2, 2025, Silexion Therapeutics Corp (the " Company ") posted to its website (https://silexion.com/) an updated corporate presentation that it will be presenting on September 10, 2025 at the H.C. Wainwright Global Investment Conference taking place from September 8-10, 2025, in New York. A copy of the presentation is furnished with this Form 8-K as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K that is furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits 99.1 Corporate Presentation 104 Cover Page Interactive Data File (formatted in Inline XBRL) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SILEXION THERAPEUTICS CORP Date: September 2, 2025 By: /s/ Ilan Hadar Name: Ilan Hadar Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing